Do analysts prefer NXTC or GRDX?

NextCure presently has a consensus target price of $19.00, suggesting a potential upside of 186.58%. Given NextCure's stronger consensus rating and higher probable upside, analysts plainly believe NextCure is more favorable than Entero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NextCure 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is NXTC or GRDX more profitable?

Entero Therapeutics' return on equity of -49.81% beat NextCure's return on equity. Company Net Margins Return on Equity Return on Assets NextCure N/A -186.96% -124.62% Entero Therapeutics N/A -49.81% -11.02%

Which has preferable earnings and valuation, KYNB or NXTC?

Kyntra Bio has higher revenue and earnings than NextCure. NextCure is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kyntra Bio $6.44M 4.53 $183.45M $40.46 0.18 NextCure N/A N/A -$55.84M -$17.19 N/A

Is KYNB or NXTC more profitable?

Kyntra Bio has a net margin of 2,199.13% compared to NextCure's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat NextCure's return on equity. Company Net Margins Return on Equity Return on Assets Kyntra Bio 2,199.13% N/A -36.71% NextCure N/A -186.96% -124.62%

Does the media refer more to KYNB or NXTC?

In the previous week, NextCure had 5 more articles in the media than Kyntra Bio. MarketBeat recorded 7 mentions for NextCure and 2 mentions for Kyntra Bio. Kyntra Bio's average media sentiment score of 0.93 beat NextCure's score of 0.72 indicating that Kyntra Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyntra Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NextCure 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer TAOX or NXTC?

NextCure has a consensus target price of $19.00, indicating a potential upside of 186.58%. Given NextCure's stronger consensus rating and higher probable upside, analysts plainly believe NextCure is more favorable than Synaptogenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NextCure 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is TAOX or NXTC more profitable?

Synaptogenix's return on equity of -163.40% beat NextCure's return on equity. Company Net Margins Return on Equity Return on Assets Synaptogenix N/A -163.40% -133.47% NextCure N/A -186.96% -124.62%

Which has better valuation & earnings, NXTC or KALA?

NextCure is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NextCure N/A N/A -$55.84M -$17.19 N/A KALA BIO N/A N/A -$26.98M -$96.14 N/A

Is NXTC or KALA more profitable?

NextCure's return on equity of -186.96% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets NextCure N/A -186.96% -124.62% KALA BIO N/A -1,336.10% -94.85%

Does the media refer more to NXTC or KALA?

In the previous week, NextCure had 4 more articles in the media than KALA BIO. MarketBeat recorded 7 mentions for NextCure and 3 mentions for KALA BIO. NextCure's average media sentiment score of 0.72 beat KALA BIO's score of 0.47 indicating that NextCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NextCure 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive KALA BIO 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate NXTC or CPHI?

NextCure currently has a consensus target price of $19.00, suggesting a potential upside of 186.58%. Given NextCure's stronger consensus rating and higher probable upside, equities analysts plainly believe NextCure is more favorable than China Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NextCure 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is NXTC or CPHI more profitable?

NextCure has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat NextCure's return on equity. Company Net Margins Return on Equity Return on Assets NextCure N/A -186.96% -124.62% China Pharma -85.56% -63.93% -31.42%

Does the media refer more to NXTC or CPHI?

In the previous week, NextCure had 5 more articles in the media than China Pharma. MarketBeat recorded 7 mentions for NextCure and 2 mentions for China Pharma. NextCure's average media sentiment score of 0.72 beat China Pharma's score of 0.19 indicating that NextCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NextCure 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive China Pharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

NextCure (NXTC) Competitors

$6.63 +0.05 (+0.76%)

Closing price 04:00 PM Eastern

Extended Trading

$6.40 -0.23 (-3.48%)

As of 07:59 PM Eastern

Compare

NXTC vs. GRDX, KYNB, TAOX, KALA, and CPHI

Should you buy NextCure stock or one of its competitors? MarketBeat compares NextCure with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NextCure include Entero Therapeutics (GRDX), Kyntra Bio (KYNB), Synaptogenix (TAOX), KALA BIO (KALA), and China Pharma (CPHI). These companies are all part of the "pharmaceutical products" industry.

How does NextCure compare to Entero Therapeutics?

NextCure (NASDAQ:NXTC) and Entero Therapeutics (NASDAQ:GRDX) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

Entero Therapeutics' return on equity of -49.81% beat NextCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NextCure	N/A	-186.96%	-124.62%
Entero Therapeutics	N/A	-49.81%	-11.02%

NextCure has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.81, indicating that its share price is 81% more volatile than the broader market.

NextCure presently has a consensus target price of $19.00, suggesting a potential upside of 186.58%. Given NextCure's stronger consensus rating and higher probable upside, analysts plainly believe NextCure is more favorable than Entero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NextCure	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Entero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

42.7% of NextCure shares are held by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are held by institutional investors. 11.9% of NextCure shares are held by insiders. Comparatively, 0.8% of Entero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Entero Therapeutics has higher revenue and earnings than NextCure. Entero Therapeutics is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NextCure	N/A	N/A	-$55.84M	-$17.19	N/A
Entero Therapeutics	$40K	699.64	-$6.39M	-$1.88	N/A

In the previous week, NextCure had 6 more articles in the media than Entero Therapeutics. MarketBeat recorded 7 mentions for NextCure and 1 mentions for Entero Therapeutics. Entero Therapeutics' average media sentiment score of 1.87 beat NextCure's score of 0.72 indicating that Entero Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
NextCure	Positive
Entero Therapeutics	Very Positive

Summary

NextCure and Entero Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does NextCure compare to Kyntra Bio?

Kyntra Bio (NASDAQ:KYNB) and NextCure (NASDAQ:NXTC) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, institutional ownership, valuation, risk, analyst recommendations and earnings.

Kyntra Bio has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market. Comparatively, NextCure has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market.

In the previous week, NextCure had 5 more articles in the media than Kyntra Bio. MarketBeat recorded 7 mentions for NextCure and 2 mentions for Kyntra Bio. Kyntra Bio's average media sentiment score of 0.93 beat NextCure's score of 0.72 indicating that Kyntra Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyntra Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NextCure	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

72.7% of Kyntra Bio shares are held by institutional investors. Comparatively, 42.7% of NextCure shares are held by institutional investors. 4.2% of Kyntra Bio shares are held by company insiders. Comparatively, 11.9% of NextCure shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Kyntra Bio has higher revenue and earnings than NextCure. NextCure is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyntra Bio	$6.44M	4.53	$183.45M	$40.46	0.18
NextCure	N/A	N/A	-$55.84M	-$17.19	N/A

Kyntra Bio has a net margin of 2,199.13% compared to NextCure's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat NextCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,199.13%	N/A	-36.71%
NextCure	N/A	-186.96%	-124.62%

Kyntra Bio presently has a consensus price target of $32.50, indicating a potential upside of 350.76%. NextCure has a consensus price target of $19.00, indicating a potential upside of 186.58%. Given Kyntra Bio's stronger consensus rating and higher possible upside, research analysts plainly believe Kyntra Bio is more favorable than NextCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
NextCure	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Kyntra Bio beats NextCure on 12 of the 15 factors compared between the two stocks.

How does NextCure compare to Synaptogenix?

Synaptogenix (NASDAQ:TAOX) and NextCure (NASDAQ:NXTC) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

In the previous week, NextCure had 6 more articles in the media than Synaptogenix. MarketBeat recorded 7 mentions for NextCure and 1 mentions for Synaptogenix. Synaptogenix's average media sentiment score of 0.94 beat NextCure's score of 0.72 indicating that Synaptogenix is being referred to more favorably in the media.

Company	Overall Sentiment
Synaptogenix	Positive
NextCure	Positive

Synaptogenix has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market. Comparatively, NextCure has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market.

Synaptogenix's return on equity of -163.40% beat NextCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synaptogenix	N/A	-163.40%	-133.47%
NextCure	N/A	-186.96%	-124.62%

NextCure has a consensus target price of $19.00, indicating a potential upside of 186.58%. Given NextCure's stronger consensus rating and higher probable upside, analysts plainly believe NextCure is more favorable than Synaptogenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NextCure	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

10.3% of Synaptogenix shares are owned by institutional investors. Comparatively, 42.7% of NextCure shares are owned by institutional investors. 2.7% of Synaptogenix shares are owned by insiders. Comparatively, 11.9% of NextCure shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Synaptogenix has higher revenue and earnings than NextCure. NextCure is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synaptogenix	$300K	95.37	-$28.74M	-$13.28	N/A
NextCure	N/A	N/A	-$55.84M	-$17.19	N/A

Summary

NextCure beats Synaptogenix on 7 of the 13 factors compared between the two stocks.

How does NextCure compare to KALA BIO?

NextCure (NASDAQ:NXTC) and KALA BIO (NASDAQ:KALA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

NextCure's return on equity of -186.96% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NextCure	N/A	-186.96%	-124.62%
KALA BIO	N/A	-1,336.10%	-94.85%

NextCure has a beta of 1.42, meaning that its share price is 42% more volatile than the broader market. Comparatively, KALA BIO has a beta of -2.35, meaning that its share price is 335% less volatile than the broader market.

42.7% of NextCure shares are owned by institutional investors. Comparatively, 24.6% of KALA BIO shares are owned by institutional investors. 11.9% of NextCure shares are owned by company insiders. Comparatively, 2.2% of KALA BIO shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

NextCure is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NextCure	N/A	N/A	-$55.84M	-$17.19	N/A
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A

In the previous week, NextCure had 4 more articles in the media than KALA BIO. MarketBeat recorded 7 mentions for NextCure and 3 mentions for KALA BIO. NextCure's average media sentiment score of 0.72 beat KALA BIO's score of 0.47 indicating that NextCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NextCure	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
KALA BIO	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NextCure presently has a consensus price target of $19.00, indicating a potential upside of 186.58%. KALA BIO has a consensus price target of $1,158.33, indicating a potential upside of 112,359.55%. Given KALA BIO's higher possible upside, analysts plainly believe KALA BIO is more favorable than NextCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NextCure	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

NextCure beats KALA BIO on 9 of the 13 factors compared between the two stocks.

How does NextCure compare to China Pharma?

NextCure (NASDAQ:NXTC) and China Pharma (NYSE:CPHI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

In the previous week, NextCure had 5 more articles in the media than China Pharma. MarketBeat recorded 7 mentions for NextCure and 2 mentions for China Pharma. NextCure's average media sentiment score of 0.72 beat China Pharma's score of 0.19 indicating that NextCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NextCure	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
China Pharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NextCure currently has a consensus target price of $19.00, suggesting a potential upside of 186.58%. Given NextCure's stronger consensus rating and higher probable upside, equities analysts plainly believe NextCure is more favorable than China Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NextCure	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

NextCure has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat NextCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NextCure	N/A	-186.96%	-124.62%
China Pharma	-85.56%	-63.93%	-31.42%

NextCure has a beta of 1.42, suggesting that its share price is 42% more volatile than the broader market. Comparatively, China Pharma has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market.

China Pharma has higher revenue and earnings than NextCure. China Pharma is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NextCure	N/A	N/A	-$55.84M	-$17.19	N/A
China Pharma	$3.99M	11.17	-$3.08M	-$0.55	N/A

42.7% of NextCure shares are held by institutional investors. 11.9% of NextCure shares are held by insiders. Comparatively, 6.4% of China Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

NextCure beats China Pharma on 10 of the 15 factors compared between the two stocks.

Get NextCure News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NXTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NXTC vs. The Competition

Export

Metric	NextCure	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$23.93M	$3.68B	$6.77B	$12.66B
Dividend Yield	N/A	2.19%	2.68%	8.42%
P/E Ratio	-0.39	21.50	27.12	24.37
Price / Sales	N/A	327.19	527.71	93.32
Price / Cash	N/A	143.66	48.59	59.39
Price / Book	0.66	8.57	10.82	6.32
Net Income	-$55.84M	$23.88M	$3.59B	$331.55M
7 Day Performance	272.47%	-2.32%	-1.21%	0.15%
1 Month Performance	234.85%	6.47%	3.13%	-0.68%
1 Year Performance	39.29%	53.33%	29.12%	20.73%

NextCure Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NXTC NextCure	3.6008 of 5 stars	$6.63 +0.8%	$19.00 +186.6%	+34.3%	$23.93M	N/A	N/A	90	News Coverage Analyst Forecast Gap Down High Trading Volume
GRDX Entero Therapeutics	1.1169 of 5 stars	$4.35 -2.2%	N/A	N/A	$29.61M	$40K	N/A	9	Gap Down
KYNB Kyntra Bio	3.5603 of 5 stars	$7.54 +4.0%	$32.50 +331.0%	N/A	$29.35M	$6.44M	N/A	570
TAOX Synaptogenix	0.4128 of 5 stars	$3.63 -5.7%	N/A	N/A	$28.77M	$300K	N/A	4
KALA KALA BIO	2.0839 of 5 stars	$1.51 -1.9%	$1,018.75 +67,366.9%	-99.7%	$28.63M	N/A	N/A	30	News Coverage Analyst Downgrade Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NXTC) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NextCure (NXTC) Competitors

NXTC vs. GRDX, KYNB, TAOX, KALA, and CPHI

How does NextCure compare to Entero Therapeutics?

Summary

How does NextCure compare to Kyntra Bio?

Summary

How does NextCure compare to Synaptogenix?

Summary

How does NextCure compare to KALA BIO?

Summary

How does NextCure compare to China Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NXTC vs. The Competition

NextCure Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NextCure (NXTC) Competitors

NXTC vs. GRDX, KYNB, TAOX, KALA, and CPHI

How does NextCure compare to Entero Therapeutics?

Is NXTC or GRDX more profitable?

Which has more volatility and risk, NXTC or GRDX?

Do analysts prefer NXTC or GRDX?

Do institutionals and insiders have more ownership in NXTC or GRDX?

Which has stronger valuation and earnings, NXTC or GRDX?

Does the media favor NXTC or GRDX?

Summary

How does NextCure compare to Kyntra Bio?

Which has more risk & volatility, KYNB or NXTC?

Does the media refer more to KYNB or NXTC?

Do institutionals and insiders believe in KYNB or NXTC?

Which has preferable earnings and valuation, KYNB or NXTC?

Is KYNB or NXTC more profitable?

Do analysts recommend KYNB or NXTC?

Summary

How does NextCure compare to Synaptogenix?

Does the media refer more to TAOX or NXTC?

Which has more volatility and risk, TAOX or NXTC?

Is TAOX or NXTC more profitable?

Do analysts prefer TAOX or NXTC?

Do institutionals and insiders believe in TAOX or NXTC?

Which has preferable valuation and earnings, TAOX or NXTC?

Summary

How does NextCure compare to KALA BIO?

Is NXTC or KALA more profitable?

Which has more risk and volatility, NXTC or KALA?

Do insiders & institutionals believe in NXTC or KALA?

Which has better valuation & earnings, NXTC or KALA?

Does the media refer more to NXTC or KALA?

Do analysts prefer NXTC or KALA?

Summary

How does NextCure compare to China Pharma?

Does the media refer more to NXTC or CPHI?

Do analysts rate NXTC or CPHI?

Is NXTC or CPHI more profitable?

Which has more volatility & risk, NXTC or CPHI?

Which has better earnings and valuation, NXTC or CPHI?

Do insiders & institutionals hold more shares of NXTC or CPHI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NXTC vs. The Competition

NextCure Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools